Our innovative GLP-1/GIP/Glucagon triple agonist NVP-305 dosed the first patient in its Phase IIa obesity trial (NVP-305-201), a randomized, double-blind, placebo-controlled study enrolling 240 obese or overweight adults over 48 weeks.
Preclinical data showed superior weight reduction versus marketed dual agonists in animal models, with notable lean mass preservation, positioning NVP-305 as a potential benchmark for next-generation weight management.
Development for type 2 diabetes is progressing in parallel, with Phase III entry anticipated in 2027.